Partnering News

01.06.2016

NextCure, Inc., New Immuno-Oncology Firm Announces $67 Million Series A Financing

01.04.2016

KineMed Enters Into Strategic Proteomic Biomarker Discovery Collaboration with Pfizer Inc.

01.04.2016

Absorption Systems Licenses Cell Line to Pfizer

12.08.2015

BIOATLA ENTERS INTO STRATEGIC LICENSE AND OPTION AGREEMENT WITH PFIZER FOR A NEW CLASS OF ANTIBODY THERAPEUTICS

12.08.2015

Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer for Progress in Hemophilia B Gene Therapy Program

11.30.2015

HEPTARES ENTERS STRATEGIC DRUG DISCOVERY COLLABORATION WITH PFIZER INC. FOCUSED ON GPCR TARGETS ACROSS MULTIPLE THERAPEUTIC AREAS

11.30.2015

Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas

11.18.2015

Thermo Fisher Scientific Signs Development Agreement for Next-Generation Sequencing-Based Companion Diagnostic

11.10.2015

Uwe Schoenbeck from Pfizer Inc. appointed member of CQDM’s Board of Directors

10.29.2015

GLYCOMIMETICS, INC. ANNOUNCES INITIATION OF FIRST CLINICAL TRIAL EVALUATING SUBCUTANEOUS ADMINISTRATION OF RIVIPANSEL

10.29.2015

HALOZYME ANNOUNCES FIRST CLINICAL DOSING OF PFIZER’S RIVIPANSEL USING ENHANZE™TECHNOLOGY

10.13.2015

Pelago Bioscience grants Pfizer Inc. license to the CETSA™ method